Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial

Lancet

Volumn 362, Issue 9383, 2003, Pages 516-522

  Ardeshna, Kirit M ^a   Smith, P ^a   Norton, A ^a   Hancock, B W ^a   Hoskin, P J ^a   MacLennan, K A ^a   Marcus, R E ^a   Jelliffe, A ^a   Vaughan Hudson, G ^a   Linch, D C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; SYSTEMIC THERAPY; TREATMENT PLANNING;

EID: 0041656437     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14110-4     Document Type: Article

References (19)

1. Horning S.J. Follicular lymphoma: have we made any progress? Ann Oncol. 11:(suppl 1):2000;23-27.
2. Linch D. Current treatment of follicular and low-grade non-Hodgkin's lymphoma. Anticancer Drugs. 12:(suppl 2):2001;5-9.
3. Portlock C.S., Rosenberg S.A. No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med. 90:1979;10-13.
4. Horning S.J., Rosenberg S.A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 311:1984;1471-1475.
5. Brice P., Bastion Y., Lepage E., et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. J Clin Oncol. 15:1997;1110-1117.
6. O'Brien M.E., Easterbrook P., Powell J., et al. The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival. QJM. 80:1991;651-660.
7. Young R.C., Longo D.L., Glatstein E., Ihde D.C., Jaffe E.S., DeVita V.T. Jr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 25:(suppl 2):1988;11-16.
8. Bennett M.H., Farrer-Brown G., Henry K., Jelliffe A.M. Classification of non-Hodgkin's lymphomas. Lancet. 2:1974;405-406.
9. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 49:1982;2112-2135.
10. Leonard R.C., Hayward R.L., Prescott R.J., Wang J.X. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. Ann Oncol. 2:1991;655-662.
11. Kimby E., Bjorkholm M., Gahrton G., et al. Chlorambucil/prednisone vs CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol. 5:(suppl 2):1994;67-71.
12. Peterson B.A., Petroni G.R., Frizzera G., et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol. 21:2003;5-15.
13. Symmers D. Giant follicular lymphadenopathy with or without splenomegaly. Arch Path. 26:1938;603-647.
14. Holmes J.A., Whittaker J.A. Spontaneous remission in chronic lymphocytic leukaemia. Br J Haematol. 69:1988;97-98.
15. Hunault-Berger M., Ifrah N., Solal-Celigny P. Intensive therapies in follicular non-Hodgkins lymphoma. Blood. 100:2002;1141-1152.
16. van Besien K., Sobocinski K.A., Rowlings P.A., et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 92:1998;1832-1836.
17. Khouri I.F., Saliba R.M., Giralt S.A., et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 98:2001;3595-3599.
18. Czuczman M.S. Immunochemotherapy in indolent non-Hodgkin's lymphoma. Semin Oncol. 29:(suppl 6):2002;11-17.
19. Solal-Celigny P. Rituximab as first-line immunotherapy in low-grade follicular lymphoma with a low tumour burden. Anti Cancer Drugs. 12:(suppl 2):2001;511-514.